AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04689594 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CLS2702C/CLS2702D
Description: CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months \[24 weeks\]); follow-up period, 6 months \[24 weeks\]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device
Study NCT06490120 — intervention group
Intervention type: OTHER
Intervention: sampling method
Description: feasibility outcomes will be compared between the 3 groups
Study NCT05940727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual macroalgae consumption
Description: The participant have a habitual macroalgae consumption at baseline.
Study NCT05940727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Habitual macroalgae consumption
Description: The participant have a habitual macroalgae consumption at baseline.
Study NCT05940727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No macroalgae consumption
Description: The participants exclude any macroalgae products from their diet
Study NCT05940727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No macroalgae consumption
Description: The participants exclude any macroalgae products from their diet
Study NCT06012721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: Food effect healthy subjects
Study NCT05618236 — intervention group
Intervention type: DRUG
Intervention: Group N; neostigmine+atropine
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.
Study NCT05618236 — intervention group
Intervention type: DRUG
Intervention: GROUP S; decurarized with sugammadex.
Description: The patients included in the study will be divided into 2 groups according to the agent used in decurarization. There is no condition for the number of patients in the group to be equal. Group N; neostigmine+atropine, GROUP S; This will be the group of patients decurarized with sugammadex.~0-45 days after patients are extubated. And at the 2nd hour, FLACC Scale (Pain Diagnostic Scale), PAED (Pediatric Anesthesia Recovery Delirium) Scale assessment methods will be compared in terms of pain and agitation. Nausea and vomiting will be noted as yes/no.
Study NCT05996588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1 % Injectable Suspension
Description: Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously
Study NCT05821946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections
Description: Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
Study NCT05067335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Romosozumab
Description: Subjects will receive romosozumab in a specified sequence during the treatment Period.
Study NCT05067335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Subjects will receive romosozumab in a specified sequence during the treatment Period.
Study NCT05067335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo in a specified sequence during the treatment Period.
Study NCT05021939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-Dimensional Group
Description: In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
Study NCT05021939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Group
Description: In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
Study NCT05641610 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ZS801
Description: A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose levels are as follows: 2.0×10\^12vg/kg, 5.0×10\^12vg/kg, 1.0×10\^13vg/kg.
Study NCT06324058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral cryoablation
Description: Using an intracavitary cryoablation balloon, cryoablation is performed on the wound surface after tumor resection. The wound surface is frozen for 2 rounds, with each round lasting 3 minutes, to fully cover the wound surface.
Study NCT05996588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25
Study NCT06324058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of bladder tumor
Description: Resection of bladder tumor using resectoscopy, which is a standard procedure to treat non-muscle invasive bladder cancer
Study NCT06324058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral resection of bladder tumor
Description: Resection of bladder tumor using resectoscopy, which is a standard procedure to treat non-muscle invasive bladder cancer
Study NCT06324058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bcg Intravesical
Description: Bacillus Calmette-Guerin instillation of bladder after surgery according to the NCCN bladder cancer guidelines. At least 6 weeks induction instillation is required for high-risk NMIBC patients. At least 1 year maintenance instillation is recommended.
Study NCT06324058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bcg Intravesical
Description: Bacillus Calmette-Guerin instillation of bladder after surgery according to the NCCN bladder cancer guidelines. At least 6 weeks induction instillation is required for high-risk NMIBC patients. At least 1 year maintenance instillation is recommended.
Study NCT05741996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taping
Description: Taping types and brace acute effects for knee osteoartritis
Study NCT04267263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided lifestyle intervention
Description: The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
Study NCT05504941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic, cerebral Digital Subtraction Angiography (DSA)
Description: The DSA is the goldstandard for the visualization of brain vessels. For performing a diagnostic cerebral DSA, the femoral artery of the patient will be punctured in the groin. Over this arterial access a catheter will be advanced under fluoroscopy guidance to the target vessel in the brain. After navigation to the targeted brain vessel, contrast media will be injected over the catheter into the vessel. The efflux of the contrast media will be monitored and visualized with fluoroscopy. The additional radiation to the patient due to the DSA will be approx. 1.1 mSv. The duration of the DSA will be 15 to 20 minutes.
Study NCT06223113 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EyenableTM PA60AS1 IOL
Description: Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.
Study NCT06725459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic ciNPWT
Description: The prophylactic closed incision negative pressure wound therapy (ciNPWT) will be applied to one breast for up to 7 days postoperatively to promote wound healing and prevent complications.
Study NCT06725459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Adhesive Dressing
Description: The standard adhesive strip dressing will be applied to one breast immediately after surgery. It provides a protective covering for the wound during the initial healing phase and is the standard of care for incision management.
Study NCT06735027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraarticular corticosteroid injection (IACI)
Description: The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the glenohumeral joint. The injection site will then be disinfected with an alcohol wipe. A 21, 22, or 23-gauge needle (depending on provider preference) will be advanced into the glenohumeral joint under direct ultrasound visualization. After entry into the glenohumeral joint, a negative aspiration will be performed. At that time, up to 1 mL of 40mg/mL methylprednisolone acetate will be injected be injected into the joint space.
Study NCT06735027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suprascapular nerve block (SSNB)
Description: The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the suprascapular nerve in its path at the suprascapular notch. After disinfection of the injection site with alcohol, anatomic landmarks for SSNB as described by Dangoisse et al. \[10\] will be marked with a marking pen. Ultrasound will be utilized to guide the tip of a 21, 22, or 23 gauge (depending on provider preference) needle to the floor of the suprascapular fossa while avoiding neurovascular structures. At that time, a mixture of up to 10 mL of 0.5% bupivacaine and 20 mg triamcinolone will be slowly injected to fill the fascial contents of the suprascapular fossa under direct ultrasound guidance.
Study NCT03941132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously.
Study NCT03941132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously.
Study NCT06018987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-Treatment Control
Description: Participants will not receive treatment for 6 months and then will be offered an optional delayed treatment of HAC 20L after completion of of Month 6 visit with an optional touch-up treatment offered 30 days after delayed treatment.
Study NCT06018987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAC 20L
Description: Subdermal Injections
Study NCT04705376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breg Polarcare
Description: The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
Study NCT04705376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Polarcare
Description: The Breg Polarcare device is a type of cryotherapy machine that circulates ice cold water into a patch that can be worn by the patient on their affected joint (e.g., shoulder, knee).
Study NCT04705376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermazone
Description: ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
Study NCT04705376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermazone
Description: ThermaZone is a compact device that uses thermoelectric technology to provide heating and cooling therapy without the use of ice.
Study NCT04155177 — intervention group
Intervention type: PROCEDURE
Intervention: training for french ambulatory caesarean section
Description: The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS procedure with one of the two senior surgeons assigned for the study.~In a second step, the trainee will have to perform all the steps of the FAUCS, assisted by one of the two senior surgeons . During each surgery, Operative time will be measured, while an evaluation on four stages according to the Zwisch model of supervision will performed by the senior surgeons .~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone FAUCS procedures and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications.~finally, total number of FAUCS procedures required for each resident in order to master the technique will be determined.
Study NCT05486364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digital Monitoring
Description: Subjects will perform self-measurements with a PPG based smartphone application (FibriCheck™) to monitor for AF recurrence after the PVI procedure. One-minute measurements will be performed twice daily starting one month before the PVI procedure and continue up to 12 months after the procedure.
Study NCT05486364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Subjects will wear a 24-hour holter monitor at 3, 6 and 12 months after the PVI procedure. Additionally, outpatient cardiology clinic visits are organised at 6 weeks, 3 months and 12 months after the PVI procedure (including a 12-lead ECG and cardiologist consultation).
Study NCT06754670 — intervention group
Intervention type: DRUG
Intervention: Sodium Glycerophosphate 216 MG/ML
Description: Low phosphorus patients receive intravenous phosphate supplementation according to the clinical phosphate supplementation protocol at our center: patients with blood phosphorus \< 0.4mmol/L receive 40mmol of glycerol phosphate sodium intravenously via infusion or injection over 4-6 hours; patients with blood phosphorus 0.4-0.8mmol/L receive 30mmol of glycerol phosphate sodium intravenously via infusion or injection; Normal phosphorus patients do not require any special treatment.
Study NCT06759948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows:~1. Dose group 1: 1 × 10\^5/kg;~2. Dose group 2: 2 × 10\^5/kg;~3. Dose group 3: 3 × 10\^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10\^5 × body weight(kg); for subjects weighing >70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10\^5 × 70 kg.
Study NCT06759818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: ①The first adjustment requires electrical stimulation to break through the skin barrier. The first intervention is the day before the operation. The initial electrical stimulation frequency is 30Hz and the pulse width is 300μs. The frequency and pulse width are adjusted according to the individual feelings of the subject until they are tolerated by the subject. Maximum current stimulation without discomfort and lasting for 30 minutes; ② second time For the intervention, the subject is connected to the monitor after entering the surgery room. After observing that the subject\&#39;s vital signs are within the normal range, the same stimulation frequency as the first time is immediately given for 30 minutes; ③ The third intervention is after the subject\&#39;s surgery is completed. The same stimulation frequency was given in the resuscitation room until the patient was extubated and resuscitated.
Study NCT06759818 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation group
Description: ① The first intervention is also the day before the operation. The frequency and pulse width are adjusted three times without turning on the machine, and the subject is asked if they have any feelings. After adjusting the frequency three times, no operation is performed for 30 minutes; ② The second intervention For the first intervention, after the monitor is connected in the operating room, the frequency and pulse width are not set, and it lasts for 30 minutes before being taken out; ③ For the third intervention, after the subject\&#39;s surgery, earplugs are inserted in the recovery room, and the frequency and pulse width are not set. Remove the earplugs after extubation resuscitation is completed.
Study NCT06759012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EyeTeacher
Description: Participants randomized to the intervention group will receive access to the EyeTeacher system, along with their username, password, and a user manual, one week before the start of the course. They will follow instructions on the website and complete a quiz before and after each course. After completing the EyeTeacher curriculum, they will take the first examination (Examination 1) and complete a set of questionnaires. A classroom will be provided for study purposes, but no restrictions will be imposed on the study location. Following the EyeTeacher section, participants will attend the ophthalmology course in the regular training program, with support from the EyeTeacher system. They will be evaluated according to the ophthalmology posting's evaluation criteria (Examination 2).
Study NCT05496400 — intervention group
Intervention type: RADIATION
Intervention: Echocardiographic and Doppler studies
Description: Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~1. Cardiac output:~2. Cerebral, intestinal and renal blood flow velocities:
Study NCT06759870 — intervention group
Intervention type: OTHER
Intervention: Collection of saliva
Description: An unstimulated saliva sample will be obtained for 1 minute before implant surgery and immediately after implant surgery.
Study NCT06759870 — intervention group
Intervention type: OTHER
Intervention: Collection of gingival samples
Description: Gingival samples will be obtained by punch biopsy 3 months after implant surgery.
Study NCT05176964 — intervention group
Intervention type: RADIATION
Intervention: split-course HFRT
Description: 7Gy/F, d7, q3w, 5 cycles
Study NCT05176964 — intervention group
Intervention type: DRUG
Intervention: CAPOX chemotherapy
Description: CAPOX chemotherapy will commence on day 1 for each of six cycles: oxaliplatin 130 mg/m\^2 intravenous infusion on day 1,followed by capecitabine 1000 mg/m\^2 administered orally twice daily on day 1 to 14 of a 21-day cycle.
Study NCT05176964 — intervention group
Intervention type: DRUG
Intervention: Tislelizumab
Description: Tislelizumab 200 mg intravenous infusion on day 1 of each 21-day cycle for each of six cycles.
Study NCT05564286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
Study NCT05564286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tropisetron
Description: All patients received tropisetron 5mg on day 1.
Study NCT05564286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tropisetron
Description: All patients received tropisetron 5mg on day 1.
Study NCT05564286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: .All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
Study NCT05564286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: .All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
Study NCT05439694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
Study NCT06759870 — intervention group
Intervention type: OTHER
Intervention: ISQ registration
Description: ISQ value will be record in placement dental implant.
Study NCT06760221 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body raiotherapy
Description: Neoadjuvant stereotactic body radiation therapy followed by radical surgery for soft tissue sarcoma.